Enanta Pharmaceuticals (ENTA) Interest Expenses (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 10 years of Interest Expenses data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 93.47% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 20.81% YoY), and the FY2025 full-year result was $7.7 million, down 29.79% from the prior year.
• Interest Expenses for Q1 2026 stood at $3.3 million, up from $3.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $3.4 million in Q4 2023 and bottomed at $1.6 million in Q2 2025.
• The 4-year median for Interest Expenses is $2.5 million (2024), against an average of $2.5 million.
• The widest annual swing landed in 2024, when Interest Expenses plunged 42.98%; it then soared 93.47% in 2026.
• A 4-year view of Interest Expenses shows it stood at $3.4 million in 2023, then slumped by 42.98% to $2.0 million in 2024, then jumped by 57.14% to $3.1 million in 2025, then increased by 7.56% to $3.3 million in 2026.
• The last three Interest Expenses figures came in at $3.3 million (Q1 2026), $3.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.

Peer Comparison